Modern stem cell technology is rapidly evolving and holds promise to revolutionize medicine by allowing regeneration of any type of cell within the human body

Scientific Advisory Board

Joe Nieusma, Ph.D. Dr. Nieusma earned his BS degree from Central Michigan University and Ph.D. from University of Colorado School of Pharmacy.  He previously worked with Geneva/Sandoz Pharmaceuticals in Broomfield, CO as an industrial toxicologist and now operates Superior Toxicology and Wellness, an international consultant firm located in Superior CO.  He has extensive experience as an industrial toxicologist, an expert witness for drug-related litigation & chemical exposure cases and as an environmental health & safety professional.

Dr. Nieusma assists Vitro regarding business development and expansion of sales and marketing of existing and new products. Dr. Nieusma is especially well-connected to the pharmaceutical industry and assists the Company’s commercialization of newly developed stem cell-derived terminally differentiated cell systems for use in drug discovery, development and toxicology studies.

Pam Rice, Ph.D.  Dr. Rice holds a Ph.D. in Molecular Toxicology from the Department of Pharmaceutical Sciences at the University of Colorado and a B.S. degree in genetics from the University of California at Davis.  She is presently an Assistant Professor in the Department of Medicine at the University of Colorado Health Sciences Center.

Dr. Rice has authored numerous peer-reviewed papers in her nearly twenty-year career as a cancer researcher in journals including “Cancer Research” and “Molecular Cancer Therapeutics.”  Her research includes detailed studies of the mechanisms of cancer cell death induced by non-steroidal anti-inflammatory drugs and novel therapeutic targets for colon cancer.  The latter includes pathways involved in regulating cell proliferation and cell survival.

Dr. Rice provides Vitro with technical consultation in molecular and cellular biology as needed in the development of its stem cell products and technology for application to cancer research and treatment.

Duane Knight, CPA Mr. Knight has more than twenty-five years experience in consulting, accounting and corporate finance.  From 2009 to the present, Mr. Knight served as the Operational Chief Financial Officer of Neuromonics, Inc., a privately held Australian firm, that is one of the only firms to offer an FDA-approved treatment of tinnitus, an often debilitating condition with continual ringing in the ears without auditory input.  He oversees operations, finance (including a $2-million fund raise), accounting, auditing interface, HR and administration, corporate governance and IT.  From 2007 to 2009, he was a partner of Trinity Capital Services, LLC, a Denver, CO-based investment bank, where he headed up the life science practice, while directing FINRA compliance, numerous private placements into client firms and sell side M&A engagements.  From 2002 to 2007 he was Chief Financial Officer and VP of Finance of Denver Biomedical, Inc., a medical device firm that developed a novel catheter for the treatment of excess fluid buildup in typically terminally ill cancer patients.  During his tenure, his responsibilities included business development that yielded 25% CAGR and EBITA CAGR of 34%.  He was also responsible for gaining coverage by private insurance (Aetna) and Medicare reimbursement.  He led several significant transactions including exit of a venture partner, recapitalization with a private equity firm, debt refinancing and ultimately, sale of the company to Cardinal Health, Inc.  He was retained by Cardinal Health, Inc. to complete post-acquisition finance and integration/transition activities.  Prior to 2002, Mr. Knight established his own public accounting and consulting firm and performed finance operations for various public and private firms, and was a senior audit manager for Hein & Associates, LLP.

Mr. Knight provides assistant in the ongoing business development activities of the Company, especially as related to turn-around to profitability and the achievement of sustained earnings growth and other relevant financial activities.